Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer

Prostate

Volumn 28, Issue 4, 1996, Pages 251-265

  Denmeade, Samuel R ^a   Lin, Xiaohui S ^a   Isaacs, John T ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

apoptosis; programmed cell death; prostatic cancer

Indexed keywords

ANDROGEN;

APOPTOSIS; ARTICLE; CANCER HORMONE THERAPY; CELL DEATH; DNA DEGRADATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER;

ANDROGENS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DEATH; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 0029873670     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(199604)28:4<251::AID-PROS6>3.0.CO;2-G     Document Type: Article

References (94)

1. Wingo PA, Tong T Bolden S: Cancer statistics, 1995. CA Cancer J Clin 45:8-30, 1995.
2. Kerr JFR, Wyllie AG, Currie AR: Apoptosis: A basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 26:239-257, 1972.
3. Wyllie AH, Kerr JFR, Currie AR: Cell death: The significance of apoptosis. Int Rev Cytol 68:251-306, 1980.
4. Bowen ID, Lockshin RA: "Cell Death in Biology and Pathology." Chapman & Hall, London, 1981.
5. Wyllie AH: Glucocorticoid induces in thymocytes a nuclease-like activity associated with the chromatin condensation of apoptosis. Nature 284:555-556, 1980.
6. Kyprianou N, Isaacs JT: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122:552-562, 1988.
7. Umansky SR, Korol BA, Nelipovich PA: In vivo DNA degradation in thymocytes of -irradiated or hydrocortisone-treated rats. Biochim Biophys Acta 655:9-17, 1981.
8. Berges RS, Furuya Y, Remington L, English HF, Jacks T, Isaacs JT: Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc Natl Acad Sci USA 90:8910-8914, 1993.
9. Isaacs JT: Antagonistic effect of androgen on prostatic cell death. Prostate 5:545-557, 1984.
10. Berges RS, Vukanovic J, Epstein JI, Carmichel M, Cisek L, Johnson DE, Veltri RW, Walsh PH, Isaacs JT: Implication of the cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1:473-480, 1995.
11. Kyprianou N, Isaacs JT: Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: critical threshold concept. Prostate 11:41-50, 1987.
12. English HF, Kyprianou N, Isaacs JT: Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 15:233-251, 1989.
13. Prins GS, Birch L, Greene GL: Androgen receptor localization in different cell types of the adult rat prostate. Endocrinology 1229:3187-3199, 1991.
14. Yan G, Fukabori Y, Nikolaropoulos S, Wang F, McKeehan WL: Heparin-binding keratinocyte growth factor is a candidate stromal to epithelial cell andromedin. Mol Endocrinol 6:2123-2128, 1992.
15. Kyprinaou N, Isaacs JT: Biological significance of measurable androgen levels in the rat ventral prostate following castration. Prostate 10:313-324, 1987.
16. Kerr JFR, Searle J: Deletion of cells by apoptosis during castration-induced involution of the rat prostate. Virchows Arch Cell Pathol 13:87-102, 1973.
17. English HF, Drago JR, Santen RJ: Cellular response to androgen ablation and repletion in the rat ventral prostate: Autoradiography and morphometric analysis. Prostate 7:41-51, 1985.
18. Coffey DS, Shimazaki J, Williams-Ashman HG: Polymerization of deoxyribonucleotides in relation to androgen-induced prostatic growth. Arch Biochem Biophys 124:184-198, 1968.
19. Lesser B, Bruchovsky N: The effects of testosterone, 5a-dihydrotestosterone and adenosine 3′,5′-monophosphate on cell proliferation and differentiation in rat prostate. Biochim Biophys Acta 308:427-437, 1973.
20. Isaacs JT, Lundmo PI, Berges R, Martikainen P, Kyprianou N, English HF: Androgen regulation of programmed death of normal and malignant prostatic cells. J Andrology 13:457-464, 1992.
21. 2+-dependent endonuclease as an early event in castration-induced prostatic cell death. Prostate 13:103-117, 1988.
22. Martikainen P, Isaacs JT: Role of calcium in the programmed death of rat prostatic glandular cells. Prostate 17:175-187, 1990.
23. Kyprianou N, Isaacs JT: Identification of a cellular receptor for transforming growth factor-β in rat ventral prostate and its negative regulation by androgens. Endocrinology 123:2124-2131, 1988.
24. Pegg AE, Lockwood DH, Williams-Ashaman HG: Concentrations of putrescine and polyamines and their envmic synthesis during androgen-induced prostatic growth. Biochem J 117:17-31, 1970.
25. Chung LWK, Coffey DS: Biochemical characterization of prostatic nuclei I. Androgen-induced changes in nuclear proteins. Biochim Biophys Acta 247:570-583, 1971.
26. Snyder RD: Polyamine depletion is associated with altered chromatin structure in HeLa cells. Biochem J 260:697-704, 1989.
27. Brüne B, Hartzell P, Nicotera P, Orrenius S: Spermine prevents endonuclease activation and apoptosis in thymocytes. Exp Cell Res 195:323, 1991.
28. Lazebnik YA, Kaufman SH, Desnoyers S, Poirer GG, Earnshaw WC: Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371:346-347, 1994.
29. Nicholson DW, Ali A, Thornberry NA, et al: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376:37-43, 1995.
30. Fesus L, Thomazy V, Falus A: Induction and activation of tissue transglutaminase during programmed cell death. FEBS Lett 224:104-108, 1989.
31. Savill JS, Dransfield I, Hogg N, Haslett C: Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis. Nature 343:170-173, 1990.
32. Quarmby VE, Beckman WC Jr, Wilson EM, French FS: Androgen regulation of c-myc messenger ribonucleic acid levels in rat ventral prostate. Mol Endocrinol 1:865-874, 1987.
33. Buttyan R, Zaker Z, Lockshin R, Wolgemuth D: Cascade induction of c-fos, c-myc and heat shock 70K transcripts during regression of the rat ventral prostate gland. Mol Endocrinol 2:650-657, 1988.
34. 1 mRNA as the androgen repressed mRNA by cDNA cloning and sequence analysis. J Biol Chem 262:11901-11903, 1987.
35. Montpetit ML, Lawless KR, Tenniswood M: Androgen repressed messages in the rat ventral prostate. Prostate 8:25-36, 1986.
36. Kyprianou N, Isaacs JT: Expression of transforming growth factor-β in the rat ventral prostate during castration induced programmed cell death. Mol Endocrinol 3:1515-1522, 1989.
37. Furuya Y, Isaacs JT: Differential gene regulation during programmed death (apoptosis) versus proliferation of prostatic glandular cells induced by androgen manipulation. Endocrinology 133:2660-2666, 1993.
38. Buttyan R, Olsson CA, Pintar J, Chang C, Bandyk M, Ng PY, Sawczuk IS: Induction of the TRPM-2 gene in cells undergoing programmed death. Mol Cell Biol 9:3473-3481, 1989.
39. Dowd DR, MacDonald PN, Komm BS, Haussler MR, Miesfeld R: Evidence for early induction of calmodulin gene expression in lymphocytes undergoing glucocorticoid-mediated apoptosis. J Biol Chem 266:18423-18426, 1991.
40. Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493-501, 1992.
41. Stiens R, Helpap B: Regressive changes in the prostate after castration. A study using histology, morphometrics and autoradiography with special reference to apoptosis. Pathol Res Pract 172:73-87, 1981.
42. Evans GS, Chandler JA: Cell proliferation studies in the rat prostate. II. The effects of castration and androgen replacement upon basal and secretory cell proliferation. Prostate 11:339-352, 1987.
43. Furuya Y, Walsh JC, Lin X, Nelson WG, Isaacs JT: Androgen ablation induced programmed death of prostatic glandular cells does not involve recruitment into a defective cell cycle or p53 induction. Endocrinology 136:1898-1906, 1995.
44. Lowe S, Schmitt EM, Smith SW, Osborne BA, Jacks T: p53 is required for radiation induced apoptosis in mouse thymocytes. Nature 362:847-849, 1993.
45. Crawford ED, et al: A control randomized trial of leuprolide with and without flutamide in prostatic cancer. N Engl J Med 321:419-424, 1989.
46. Isaacs JT: Hormonally responsive vs unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327-AT and G rat prostatic adenocarcinoma. Cancer Res 42, 5010-5014, 1982.
47. Raghavan D: Non-hormone chemotherapy for prostate cancer: Principles of treatment and application to the testing of new drugs. Semin Oncol 15:371-389, 1988.
48. Shackney SE, McCormack GW, Cuchural GJ: Growth rate patterns of solid tumors and their relationship to responsiveness to therapy. Ann Intern Med 89:107-115, 1978.
49. Isaacs JT, Lundmo PI: Chemotherapeutic induction of programmed cell death in non proliferating prostate cancer cells. Proc Am Assoc Cancer Res 33:588-589, 1992.
50. Tubiana M, Malaise EP: Growth rate and cell kinetics in human tumors: some prognostic and therapeutic implications. In Symington T, Carter RL (eds): "Scientific Foundation of Oncology." Chicago: YearBook Medical Publishers, 1976, pp 126-138.
51. Kyprianou N, Isaacs JT: Thymine-less death in androgen independent prostatic cancer cells. Biochem Biophys Res Commun 165:73-81, 1989.
52. Connor J, Sawczuk IS, Benson MC, Tomasahefsky P, O'Toole KM, Olsson CA, Buttyan R: Calcium channel antagonists delay regression of androgen-independent tissues and suppress gene activity associated with cell death. Prostate 13:119-130, 1988.
53. Sells SF, Wood DP, Joshi-Barve SS, et al: Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Diff 5:457, 1994.
54. Greenberg DA: Calcium channels and calcium channel antagonists. Ann Neurol 21:317-330, 1987.
55. Martikainen P, Kyprianou N, Tucker RW, Isaacs JT: Programmed death of nonproliferating androgen independent prostatic cancer cells. Cancer Res 51:4693-4700, 1991.
56. Tsujimota Y, Cossman J, Jaffe E, Croce C: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440-1443, 1985.
57. Chen-Levy S, Cleary ML: Membrane topology of the Bd-2 proto-oncogenic protein demonstrated in vitro. J Biol Chem 265:4929-4933, 1990.
58. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC: Investigations of the subcellular distribution of the BCL-2 oncoprotein: Residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 53:4701-4714, 1993.
59. Reed JC, Cuddy M, Slabiak T, Croce CM, Nowell PC: Oncogenic potential of bcl-2 demonstrated by gene transfer. Nature 336:259-261, 1988.
60. McDonnell TJ, Deane N, Platt FH, Nunes G, Jaeger U, McKearn JP, Korsmeyer SJ: Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57:79-88, 1989.
61. Vaux D, Cory S, Adams J: Bcl-2 promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440-442, 1988.
62. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334-336, 1990.
63. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 74:609-619, 1993.
64. Yin XM, Oltvai ZN, Korsmeyer SJ: BH1 and BH2 domains of bcl-2 are required for inhibition of apoptosis and heterodimerization with bax. Nature 369:321-323, 1994.
65. Miyashita T, Reed JC: Bcl-2 gene transfer increase relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52:5407-5411, 1992.
66. Miyashita T, Reed JC: Bd-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151-157, 1993.
67. Walton MI, Whysong D, O'Connor PM, et al: Constitutive expression of human bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res 53:1853-1861, 1993.
68. Hanada M, Krajewski S, Tanaka S, et al: Regulation of bd-2 oncoprotein levels with differentiation of human neuroblastoma cells. Cancer Res 53:4978-4986, 1993.
69. Levine B, Huang Q, Isaacs JT, et al: Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene. Nature 361:739-742, 1993.
70. McDonnell TJ, Troncoso P, Brisbay SM, et al: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944, 1992.
71. Colombel M, Symmans F, Gil S, et al: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143:390-400, 1993.
72. Shabaik AS, Krajewski S, Burgan A, Krajewski M, Reed JC: Bcl-2 protooncogene expression in normal, hyperplastic, and neoplastic prostate tissue. J Urol Pathol 3:17-27, 1995.
73. Isaacs JT: Role of androgens in prostatic cancer. Vitam Horm 49:433-502, 1994.
74. Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT: Expression of bcl-2 and the progression of human and rodent prostate cancers. Clin Cancer Res 2:(in press), 1996.
75. Isaacs JT, Hukku B: Nonrandom involvement of chromosome 4 in the progression of rat prostatic cancer. Prostate 13:165-188, 1988.
76. Isaacs JT, Wake N, Coffey DS, Sanberg AA: Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system. Cancer Res 42:2353-2361, 1982.
77. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1-6, 1994.
78. Miyashita T, Krajewski S, Krajewska M, et al: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799-1805, 1994.
79. Navone NM, Troncoso P, Pisters LL, et al: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85:1657-1669, 1993.
80. Folkman J: What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst 82:4-6, 1990.
81. Vukanovic J, Passaniti A, Hirata T, et al: Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res 53:1833-1837, 1993.
82. Ichikawa T, Lamb JC, Christensson PJ, Hartley-Asp B, Isaacs JT: The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers. Cancer Res 52:3022-3028, 1992.
83. Vukanovic J, Isaacs JT: Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res 55:1499-1504, 1995.
84. Furuya Y, Isaacs JT: Proliferation-dependent vs independent programmed cell death of prostatic cancer cells involves distinct gene regulation. Prostate 25:301-309, 1994.
85. Furuya Y, Lundmo P, Short AD, Gill DL, Isaacs JT: The role of calcium pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res 54:6167-6175, 1994.
86. Christensen SB, Norup E, Rasmussen U: Chemistry and structure-activity relationship of the histamine secretagogue Thapsigargin and related compounds. In Krogsgaard-Larsen P, Brogger S, Christensen, Kofod H (eds): "Natural Products and Drug Development." 1993, pp 405-418.
87. Rasmussen U, Christensen SB, Sandberg F: Thapsigargin and thapsigargicin, two new histamine liberators from Thapsia garganica. L Acta Pharm Suec 15:133, 1978.
88. 2+-ATPase. Proc Natl Acad Sci USA 87:2466-2470, 1990.
89. 2+-AT-Pase family of calcium pumps. J Biol Chem 266:17067-17071, 1991.
90. Christensson A, Laurell CB, Lilja H: Enzymatic activity of the prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 194:755-765, 1990.
91. Watt KWK, Lee PJ, Timkulu TM, Chan WP, Loor R: Human prostate-specific antigen: Structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 83:3166-3170, 1986.
92. 1-antichymotrypsin. Clin Chem 37:1618-1625, 1991.
93. Lilja H, Abrahamsson PA, Lundwall A: Semenogelin, the predominant protein in human semen. J Biol Chem 264:1894-1900, 1989.
94. 2+ ATPase. FEBS 335:345, 1993.